Moderna, mRNA

Moderna Gets $590 Million in Federal Funding for Bird Flu Vaccine
The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor people with animal exposure.
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.
Moderna gets $590M HHS contract to develop mRNA pandemic flu vaccines
Moderna receives $590M contract from HHS for mRNA-based bird flu vaccine; up 4% in after-hours trading. Read more here.
Moderna Receives $590M From HHS To Develop Bird Flu Vaccine
The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu. This funding, announced Friday by Moderna,
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development
The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.
Moderna Gets $590 Million to Develop Bird Flu Vaccine
The government is working to head off human bird flu infections. The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023.
Moderna gets $590M from US government for bird flu vaccine
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.
Moderna Stock Jumps On $590M US Award For Bird Flu Vaccine Development, But Retail Doubts Longevity Under Trump
Shares of Moderna Inc. rose over 5% on Tuesday morning, reaching levels last seen more than a week ago, following news of a $590 million award from the U.S. Health and Human Services Department to accelerate its bird flu vaccine development.
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...
Monthly Prescribing Reference9d
Moderna Provides Update on Norovirus Vaccine Candidate
Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
CNN6d
HHS invests nearly $600 million in Moderna’s bird flu vaccine development
In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect against H5 and H7 avian influenza viruses. In July, the company received $176 million from HHS toward its ...
Zacks.com on MSN6d
How to Play Moderna Stock After the Recent Sales Guidance Cut
Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.
WSB Radio3d
Dept. of Health Services awards Moderna $590 million to develop flu vaccines, bird flu vaccine
ATLANTA — A vaccine for the bird flu is in the works. The Department of Health Services has awarded $590 million to Moderna to speed up the development of flu vaccines, including one for the ...
Wall Street Journal11d
Moderna Stock Plunges After Vaccine Sales Struggle
Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its vaccines against Covid-19 and respiratory syncytial virus continue to ...
Newsweek10d
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
Moderna's revenue and stock price have steadily declined since global demand for COVID-19 vaccines has dwindled. During 2020 and 2021, the company generated massive revenues, fueled by its ...
The Boston Globe10d
Moderna shares plunge after company cuts vaccine sales outlook
Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...